Prescription Drug News and Research

RSS

NHSA and Together Rx Access collaborate to improve prescription access

The National Head Start Association (NHSA) and Together Rx Access announced today a collaboration to launch the Together Rx Access(R) FOR HEAD START Card to help eligible uninsured individuals and families associated with Head Start access immediate and meaningful savings on prescription medicines and products right at their neighborhood pharmacies.

10 Sep 2009

Catalyst Health Solutions ranks 14th on the Fortune 100 Fastest-Growing Companies list

Catalyst Health Solutions, Inc. (NASDAQ:CHSI) announced today that it was named to the Fortune 100 Fastest-Growing Companies list, making its second consecutive appearance on the annual ranking and third within the past five years. Catalyst ranked Number 14 on the list of fast-growing health care companies and Number 93 overall among all industries.

10 Sep 2009

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

SCAN Health Plan receives regulatory approval to expand in Northern California

SCAN Health Plan announced today that it has received regulatory approval to expand its Medicare Advantage Plan into San Francisco, Contra Costa and Santa Clara counties, effective January 1, 2010. This is the first entry into Northern California for the not-for-profit plan, which currently serves more than 110,000 Medicare members in California and Arizona.

10 Sep 2009

Members of Blue Shield of California to receive administrative costs of the H1N1 virus vaccine

Blue Shield of California announced today that it will cover the administrative costs of the H1N1 virus (swine flu) vaccine for all its members, regardless of which plan they have. Blue Shield will be waiving prior authorizations, copays and deductibles for office visits when members go to an in-network doctor to get H1N1 vaccinations.

9 Sep 2009

Three government trusts in Arizona sign contract with Navitus Health Solutions

Navitus Health Solutions, LLC announced today it has signed contracts to provide pharmacy benefits to three government trusts in Arizona. The contracts are with the Arizona Local Government Employee Benefit Trust (AZLGEBT), Rural Arizona Group Health Trust (RAGHT) and the Cochise Combined Trust. Together, the trusts include 16 groups (seven municipalities, seven counties and two school systems).

9 Sep 2009

Advocacy campaign to fight reimbursement cuts for POC urine drug screen devices

Millennium Laboratories, a leading provider of therapeutic drug monitoring and education to physicians and staff treating chronic pain patients, has announced the launch of an advocacy campaign to fight reimbursement cuts to point-of-care (POC) urine drug screen devices.

9 Sep 2009

FDA notifies PDUFA action date for Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).

5 Sep 2009

Drive to collect unused prescription drugs starts on October 3

In an effort to keep unused prescription drugs out of the hands of pre-teens and teenagers, DDN executive Joe Otto enlisted the support of Menomonee Falls Police Chief Anna Ruzinski, Community Memorial Hospital, and his company. As a result, Community Memorial Hospital will serve as collection site when Waukesha County kicks off its first drug collection program on October 3.

4 Sep 2009

Filing and review of belatacept's license application accepted by the FDA

Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the company’s submission of a biologic license application for belatacept, which is in ongoing phase III development for use in kidney transplantation.

4 Sep 2009

U.S. hospitals place high precedence on environmentally responsible practices

Summary: Results of a recent survey commissioned by StandPoint indicate that U.S. Hospitals are putting a higher priority on implementing environmentally responsible practices. The major initiatives fall into two groups -- Waste Stream Management and Infrastructure.

4 Sep 2009

Survey reveals health plan costs to increase in 2010

According to The Segal Company’s just-completed survey of projected 2010 health plan costs, medical plan cost trends will continue to be more than four times greater than the annual increase in average hourly earnings and in sharp contrast to changes in the consumer price index for urban consumers, which have been relatively flat or negative in the past 12 months.

4 Sep 2009

Biogen Idec's MS franchise to present at the 25th Congress of ECTRIMS

Biogen Idec today announced more than 70 platform and poster presentations from the company’s multiple sclerosis (MS) franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany.

3 Sep 2009

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester Pharmaceuticals announced today that the Oncologic Drug Advisory Committee (ODAC) appointed by the U.S. Food and Drug Administration (FDA) voted 10 in favor with one abstention to recommend approval of romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL). CTCL is a type of non-Hodgkin's lymphoma, which is a cancer of the immune system.

3 Sep 2009

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

3 Sep 2009

Drug stores consider how reform efforts may affect drug stores

If reform passes, CVS expects profits to remain steady while benefit managers worry about other drug stores' plans to go around them and negotiate directly on price.

1 Sep 2009

Walgreens to provide flue shots faster and easier this season

Walgreens (NYSE:WAG)(NASDAQ:WAG) is making it faster and easier to get a flu shot this season. The nation’s largest drugstore chain today announced it will begin offering seasonal flu shots on Sept. 1 at more than 7,000 points of care nationwide, including nearly all of its stores in 50 states and almost 350 in-store Take Care Clinics.

31 Aug 2009

Mark Farrah Associates partners with Strenuus to launch Medicare Benefits Analyzer

Mark Farrah Associates (MFA) announces the addition of Medicare Benefits Analyzer to its online product portfolio. “We are very pleased to be partnering with Strenuus to launch this new product.

31 Aug 2009

First Edition: August 31, 2009

Today's headlines hint that summer's almost over, but the heat will still be on for health reform.

31 Aug 2009

Genzyme’s supplemental NDA for treating adult AML with Clolar to be discussed by the FDA

Genzyme Corporation (Nasdaq: GENZ) announced today that its supplemental New Drug Application for Clolar® (clofarabine) will be discussed Tuesday, September 1 at a public meeting of the FDA’s Oncologic Drugs Advisory Committee in Silver Spring, Maryland. The panel is expected to consider the clinical trial results Genzyme submitted to support the approval and labeling of Clolar to treat older adult patients with acute myeloid leukemia (AML), the most common type of acute leukemia in adults.

29 Aug 2009